MARKET

NKTR

NKTR

Nektar
NASDAQ

Real-time Quotes | Nasdaq Last Sale

19.43
-0.51
-2.56%
Closed 16:52 11/14 EST
OPEN
19.80
PREV CLOSE
19.94
HIGH
19.98
LOW
19.30
VOLUME
1.99M
TURNOVER
--
52 WEEK HIGH
47.11
52 WEEK LOW
15.64
MARKET CAP
3.42B
P/E (TTM)
-7.9595
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of NKTR and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

NKTR News

  • Nektar to Webcast Presentation at Jefferies 2019 London Healthcare Conference
  • PR Newswire.1d ago
  • JP Morgan Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $28
  • Benzinga.1d ago
  • Company News For Nov 12, 2019
  • Zacks.2d ago
  • Canaccord Genuity Maintains Buy on Nektar Therapeutics, Raises Price Target to $24
  • Benzinga.2d ago

More

Industry

Biotechnology & Medical Research
-0.05%
Pharmaceuticals & Medical Research
-0.27%

Hot Stocks

Name
Price
%Change

About NKTR

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, Pain-NKTR-181 and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.
More

Webull offers Nektar Therapeutics (NKTR) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.